Search results
Results from the WOW.Com Content Network
Today, Amarin (AMRN) investors are scratching their heads as to why the stock tumbled following the announcement that the FDA has approved the label extension of the company’s fish oil drug ...
With primary care clinicians playing an ever-increasing role in the management of diabetes, staying on top of new developments in the American Diabetes Association’s (ADA) Standards of Medical ...
Stock market today: Nasdaq logs best week of 2025 as Dow, S&P 500 notch third-straight weekly gain Yahoo Finance Oil prices slip as 'demand picture remains in question' amid tariff risks
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher.
Barely a month ago, investors of Amarin (AMRN) were left dismayed following a lost patent trial against two generic drug makers seeking to sell their own versions of Amarin’s high triglycerides ...
If Treasury yields continue to rise, either stock prices need to fall or companies need to produce bigger profit growth to make up for it. All told Tuesday, the S&P 500 rose 6.69 points to 5,842.91.
The Dow Jones Industrial Average jumped 498 points, or 1.2%, and the Nasdaq composite gained 1%. Superstar stock Nvidia and other Big Tech companies led the market, which got a lift after a report ...
One week ago, Stifel analyst Derek Archila reiterated his "buy" rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked how Amarin's Q2 earnings report showed sales ...